Carl Zeiss Meditec, the ZEISS Medical Technology Segment, supplies innovative technologies and application- oriented solutions designed to help doctors enhance the quality of life of their patients.

The company said cataract surgery relied on phaco technology for more than 50 years and there is a need for new approach in the field of phaco.

IanTECH’s surgical technology has been designed to change the future of managing cataracts.

IanTECH has developed micro-­interventional devices, designed to deliver energy-­free endocapsular lens fragmentation. The company has been working on new surgical approaches to address cataract blindness.

Carl Zeiss Meditec president and CEO Ludwin Monz said: “We expect that IanTECH will complement our leading portfolio of equipment and consumables in cataract surgery, allowing us to offer physicians and patients a new standard of care.

“The technology has the potential to simplify challenging cases, reduce risk to patients and further improve outcomes while being easy to train and adapt for surgeons.”

Carl Zeiss Meditec ophthalmic devices global president James Mazzo said: “We are pleased to bring the IanTECH team and technology into the ZEISS family.”

IanTECH’s miLOOP Device is claimed to be the first in a line of ophthalmic tools for its micro­-interventional cataract surgery platform.

The miLOOP Device has been designed to provide cataract surgeons, with full ­thickness lens fragmentation of the nucleus independent of phaco energy using a super-elastic thin-filament.

The device is claimed to have been engineered to minimize capsular stress by using centripetal, out-in nucleus disassembly, where conventional techniques use centrifugal, in-out lens cutting with adjunct phaco-energy.

IanTECH CEO Brian Walsh said: “We look forward to joining ZEISS to combine our efforts in bringing superior technology to the market and we are pleased to align with the great culture and commitment at ZEISS.”

Carl Zeiss Meditec, the German company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases.

It also develops visualization solutions in the field of microsurgery. It has a workforce of 3,000 employees across the world. Last year, its revenue was €1.18bn.